US-based regents manufacturer Bio-Techne, in collaboration with Novomol-Dx, has announced the development of a new ocular biomarker assay, Bio-Marker Pathfinder (BMP), designed for point-of-care applications.
Claimed to be the first of its kind, this new kit is set to aid in the diagnosis and treatment of ophthalmic diseases.
Novomol-Dx leverages biomarkers identified over the past decade at the Narayana Nethralaya Foundation, in partnership with Grow Laboratories & Narayana Nethralaya, an India-based eye care hospital chain.
The BMP kit operates on Bio-Techne’s Ella platform, an automated immunoassay system. It utilises the company’s R&D Systems reagents. It is capable of delivering precise, reliable, and reproducible results in under 90 minutes.
Ella’s microfluidic cartridges feature separate channels for precision multiplexing, providing a hands-free system that is well-suited for clinical diagnostic use.
Novomol-Dx has developed an algorithm for the BMP kit, which includes normative data, disease-associated data, and AI-based predictive algorithms for conditions affecting the ocular surface and retina.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataBio-Techne protein sciences segment president Will Geist said: “The BMP multi-analyte kit holds great promise for the potential use of Ella in proteomic diagnostic applications.
“We are happy to partner with this leading ocular biomarker research group and eye care institute to deliver a much-needed diagnostic tool for patients impacted by these diseases.”
Narayana Nethralaya Foundation GROW research labs director Dr Arkasubhra Ghosh said: “We are excited to be able to translate the years of biomarker research in eye diseases to an application that can benefit clinicians and patients.
“The multiple biomarker diagnostic design establishes a platform for future expansion to broader disease applications across ophthalmic conditions, potentially including a non-invasive tear-based diagnosis for systemic conditions.”
Branded as BioM-Pathfinder, the comprehensive solution is claimed to have applications in diagnosing and monitoring dry eye disease, diabetic retinopathy, and patient stratification related to ocular surgeries and treatments.
Last month, Bio-Techne’s Lunaphore partnered with Nikon Instruments to enhance the availability of spatial biology services in the US.